Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Vitro Biopharma Obtains CLIA Certification Complimenting its Ongoing Stem Cell Clinical Trials
BiotechnologyCompany UpdateEarningsRegulatory

Vitro Biopharma Obtains CLIA Certification Complimenting its Ongoing Stem Cell Clinical Trials

April 2, 2019 9:30 AM

GOLDEN, CO / ACCESSWIRE / April 2, 2019 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma announced receipt of a Certificate of Compliance with CLIA (Clinical Laboratory Improvement Amendment) without deficiencies. This allows Vitro Biopharma to perform clinical laboratory testing, reporting and billing in full compliance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA) according to section 353 of the Public...

Read more
CBD-Infused Beverages Achieve Quality and Clarity Breakthrough Utilizing Pressure BioSciences' Ultra Shear Technology Platform
BiotechnologyCompany UpdateInvestor Relations

CBD-Infused Beverages Achieve Quality and Clarity Breakthrough Utilizing Pressure BioSciences' Ultra Shear Technology Platform

April 2, 2019 9:10 AM

New Video Demonstrates Revolution in Soft Drinks, Sports Drinks, and Beer with Vanishing Water-Soluble CBD Oil for Enhanced Quality and Absorption SOUTH EASTON, MA / ACCESSWIRE / April 2, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today...

Read more
Pieris Pharmaceuticals Presents Preclinical Data for GPC3/4-1BB Bispecific PRS-342 at the 2019 American Association for Cancer Research (AACR) Annual Meeting
BiotechnologyCompany Update

Pieris Pharmaceuticals Presents Preclinical Data for GPC3/4-1BB Bispecific PRS-342 at the 2019 American Association for Cancer Research (AACR) Annual Meeting

April 2, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / April 2, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced the presentation of preclinical data for PRS-342, a GPC3/4-1BB immuno-oncology bispecific drug candidate, at a poster session at the 2019 American Association for...

Read more
CORRECTION: GeneNews Announces Fourth Quarter 2018 Results and Year End Investor Call
BiotechnologyCompany Update

CORRECTION: GeneNews Announces Fourth Quarter 2018 Results and Year End Investor Call

April 2, 2019 7:30 AM

In the news release, "GeneNews Announces Fourth Quarter 2018 Results and Year End Investor Call", issued Friday, March 29, 2019 by GeneNews Limited over Accesswire, we are advised by the company that the date of the Conference Call has changed to Wednesday, April 3, 8:30 AM ET. The complete, corrected release follows: Conference Call - 8:30am, Wednesday April 3, 2019 TORONTO, ON / ACCESSWIRE / April 2, 2019 / GeneNews Limited ("GeneNews" or the...

Read more
Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019
BiotechnologyCompany Update

Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019

April 2, 2019 7:00 AM

- Clinical data highlight potential utility of T cell clonality as a predictive and prognostic biomarker of pelareorep therapy - - Using pelareorep in advance of the checkpoint inhibitor Keytruda® safely primes the immune system to target cancer cells in pancreatic cancer patients - CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 2, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously...

Read more
Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update
BiotechnologyCompany Update

Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update

April 1, 2019 7:30 AM

- Recent transformative agreement to acquire innovative XCART platform technology positions Company to drive significant momentum - XCART expected to initially target B-cell lymphomas and has the potential to address multiple tumor types with an initial global market opportunity in Non-Hodgkin Lymphoma of over $5 billion annually FRAMINGHAM, MA / ACCESSWIRE / April 1, 2019 / Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"),...

Read more
Human milk oligosaccharides for health
Biotechnology

Human milk oligosaccharides for health

March 28, 2019 5:40 AM

RHEINBREITBACH / ACCESSWIRE / March 28, 2019 / Human mothers are unique because they produce breast milk which is very different from other species on our planet. Human milk has a very high concentration of special sugars known as human milk oligosaccharides (HMOs). These HMOs are the third most abundant solid component of human milk after lactose and fat. More than 200 structurally different HMOs have been identified. The most abundant HMO is...

Read more
Dyadic Reports 2018 Year End Results and Recent Developments
BiotechnologyEarnings

Dyadic Reports 2018 Year End Results and Recent Developments

March 27, 2019 4:30 PM

Market capitalization more than doubled since January 2018 Company becomes a full reporting entity subject to the reporting requirements of Section 13(a) of the Securities and Exchange Act of 1934 Company has applied to have its common stock listed on the NASDAQ Capital Markets Exchange ("NASDAQ") Nine funded proof of concept research collaborations signed in 2018 and two new collaborations in 2019 Improved scientific data generated, reflecting...

Read more
Pressure BioSciences Names the Vogel Laboratory at New York University's Center for Genomics and Systems Biology a Center of Excellence
BiotechnologyCompany Update

Pressure BioSciences Names the Vogel Laboratory at New York University's Center for Genomics and Systems Biology a Center of Excellence

March 27, 2019 8:20 AM

Collaboration with Dr. Christine Vogel and Colleagues in NYU's Internationally Recognized "Hub of Science" Center Will Provide Scientists Immediate Access to PBI's Innovative and Proprietary Pressure-Based Platform Technologies SOUTH EASTON, MA / ACCESSWIRE / March 27, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and...

Read more
Calmare Therapeutics Receives Two Favorable Rulings In Delaware Chancery Court
BiotechnologyLawsuits

Calmare Therapeutics Receives Two Favorable Rulings In Delaware Chancery Court

March 25, 2019 11:37 AM

FAIRFIELD, CT / ACCESSWIRE / March 25, 2019 / Calmare Therapeutics Incorporated, (OTC PINK: CTTC), the pain mitigation company ("Calmare" or the "Company"), announced today that, on March 15, 2019, Calmare won two significant rulings from the Delaware Court of Chancery brought against it and certain of its directors by Stanley Yarbro, another director. The Delaware Court rejected Yarbro's motion for a summary judgment to declare that he had been...

Read more
Dyadic to Present at Three Upcoming Investor Conferences
BiotechnologyConferences

Dyadic to Present at Three Upcoming Investor Conferences

March 25, 2019 8:50 AM

JUPITER, FL / ACCESSWIRE / March 25, 2019 / Dyadic International, Inc. (the "Company") (OTCQX: DYAI), today announced that its President and Chief Executive Officer, Mark Emalfarb and Chief Accounting Officer, Ping Rawson will be presenting at the following three upcoming investor conferences: Sidoti & Company Spring Conference - Presenter - Mark Emalfarb New York City, NY Thursday, March 28, 2019  12:55 p.m. ET MicroCap Spring Summit -...

Read more
Vitro Biopharma 1st Quarter ended January 31st 2019 Financial Results of Operations
BiotechnologyCompany UpdateEarnings

Vitro Biopharma 1st Quarter ended January 31st 2019 Financial Results of Operations

March 22, 2019 2:40 PM

GOLDEN, CO / ACCESSWIRE / March 22, 2019 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st 2019 financial results of operations. Vitro Diagnostics Inc. (''Vitro Biopharma'') is pleased to announce a record 1st quarter in Stem Cell Revenues. Vitro Biopharma recorded 1st quarter revenues of $192,895 vs $87,185, an increase of 121% over the same comparative quarter last year. In addition,...

Read more
American CryoStem Completes Cooperative Framework Agreement to Expand Market Presence in Japan
BiotechnologyCompany Update

American CryoStem Completes Cooperative Framework Agreement to Expand Market Presence in Japan

March 20, 2019 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / March 20, 2019 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has completed a Cooperative Framework Agreement with Shonan Beauty Clinic, and MEDINET Co., Ltd. which will provide CRYO with greater access to...

Read more
Calmare Therapeutics Has $10.4 Million Judgment Vacated by The U.S. Court of Appeals for The Second Circuit
BiotechnologyLawsuits

Calmare Therapeutics Has $10.4 Million Judgment Vacated by The U.S. Court of Appeals for The Second Circuit

March 19, 2019 11:28 AM

FAIRFIELD, CT / ACCESSWIRE / March 19, 2019 / Calmare Therapeutics Incorporated, (OTC PINK: CTTC) (''CTI''), the pain mitigation company (''Calmare''), had a $10.4 million judgment vacated by the United States Court of Appeals for the Second Circuit (the ''Second Circuit''). On September 29, 2017, the U.S. District Court for the District of Connecticut (the ''District Court'') entered a final judgment awarding GEOMC Co., Ltd. - a South Korea...

Read more
Molecular Partners Publishes Audited Financial Results for 2018  and Annual Report 2018
BiotechnologyInvestor Relations

Molecular Partners Publishes Audited Financial Results for 2018 and Annual Report 2018

March 15, 2019 2:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 15, 2019 / Molecular Partners AG (SWX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, today published its audited Financial Results for 2018 and the company's 2018 Annual Report. The Audited Financial Results for 2018 and the company's 2018 Annual Report are available on the investors section of the company' website. Financial...

Read more
BioDelivery Sciences Reports Strong 2018 Results and 2019 Expectations
BiotechnologyEarnings

BioDelivery Sciences Reports Strong 2018 Results and 2019 Expectations

March 14, 2019 4:05 PM

BELBUCA® prescription growth further accelerated to an all-time high during the fourth quarter Company increases Belbuca 2019 net sales expectations to $80-$85 million Operating cash flow to become positive in 2019 Long-term potential for BELBUCA net sales believed to be $250 - $300 million Conference Call and Webcast scheduled for 4:30 pm ET today RALEIGH, NC / ACCESSWIRE / March 14, 2019 / BioDelivery Sciences International, Inc. (NASDAQ:...

Read more
Glauconix Biosciences Completes Pilot Study Using Nemus Biosciences' Bioengineered Cannabinoid-Based Compound for Glaucoma Treatment
BiotechnologyCompany Update

Glauconix Biosciences Completes Pilot Study Using Nemus Biosciences' Bioengineered Cannabinoid-Based Compound for Glaucoma Treatment

March 14, 2019 4:55 AM

Studyconfirms intraocular pressure-lowering effects of cannabinoid-based therapeutic, proving promising novel treatment for glaucoma ALBANY, NY / ACCESSWIRE / March 14, 2019 / Glauconix Biosciences Inc., a specialty pharmaceutical company that uses its patented platform technology to develop human 3D ocular tissues that mimic the fluid dynamics in the eye to expedite and de-risk the R&D of ophthalmic treatments while reducing development costs,...

Read more
Dyadic to Report Year End 2018 Financial Results on Wednesday March 27, 2019
BiotechnologyConference CallEarnings

Dyadic to Report Year End 2018 Financial Results on Wednesday March 27, 2019

March 13, 2019 4:30 PM

JUPITER, FL / ACCESSWIRE / March 13, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for year ended December 31, 2018 after the...

Read more
Vitro Biopharma Receives Approval for a Stem Cell Clinical Trial for Musculoskeletal Conditions by the Bahamas Ministry of Health
BiotechnologyCompany Update

Vitro Biopharma Receives Approval for a Stem Cell Clinical Trial for Musculoskeletal Conditions by the Bahamas Ministry of Health

March 12, 2019 9:30 AM

GOLDEN, CO / ACCESSWIRE / March 12, 2019 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma announced receipt of provisional approval from the National Stem Cell Ethics Committee (NSCEC) of the Ministry of Health of the Commonwealth of the Bahamas for a clinical trial entitled ''Vitro Biopharma Allogeneic Mesenchymal Stem Cell Therapy for Musculoskeletal Conditions''. This broadens Vitro Biopharma's expansion into highly regulated...

Read more
Dyadic International to Present at the 2019 LD Micro Virtual Conference
BiotechnologyConferences

Dyadic International to Present at the 2019 LD Micro Virtual Conference

March 11, 2019 9:05 AM

LOS ANGELES, CA / ACCESSWIRE / March 11, 2019 / Dyadic International (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, today announced that it will be presenting at the second annual LD Micro Virtual Conference on Wednesday, March 13, 2019 at 12:40 PM EST....

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?